Clinical presentation of PD-1/PD-L1 immune checkpoint inhibitors induced cystitis [0.03%]
PD-1/PD-L1免疫检查点抑制剂致膀胱炎的临床表现
Jian Xiao,Shanting Tang,Zhi Xia et al.
Jian Xiao et al.
This study aims to systematically analyze the clinical features of cystitis induced by anti-PD-1/PD-L1 drugs, with a view to providing a basis for early warning, diagnosis, and standardized management of this adverse reaction in clinical pr...
The therapeutic potential of exosomes in bone cancers: osteosarcoma, chondrosarcoma, and Ewing sarcoma [0.03%]
外泌体在骨肿瘤治疗中的潜力：尤因肉瘤、骨肉瘤和软骨肉瘤
Nawfal Yousif Jamil,Mohammed S Nawrooz,Ashok Kumar Bishoyi et al.
Nawfal Yousif Jamil et al.
Osteosarcoma (OS), chondrosarcoma (CHS), and Ewing sarcoma (EwS) are the most common primary bone cancers (BCs). Among primary malignant tumors of the bones, OS is the most common, mainly affecting young people (4.8 per 1,000,000). The trea...
Understanding the differentiation syndrome in acute promyelocytic leukemia: a comprehensive updated review [0.03%]
急性早幼粒细胞白血病分化综合征的研究进展及可能机制——综述更新
Nahed Damaj,Nadim Elias,Toufic Zeidan et al.
Nahed Damaj et al.
The concept of differentiation therapy emerged from the fact that hormones or cytokines may promote differentiation ex vivo, thereby irreversibly changing the phenotype of cancer cells. Its hallmark success has been the treatment of acute p...
Chunyu Yu,Jie Sun,Jinlong Tong et al.
Chunyu Yu et al.
The dysregulation of cellular epigenetic machinery has been established as a fundamental driver of oncogenesis. This recognition has propelled cancer epigenetics to the forefront of biomedical research, particularly regarding the mechanisti...
Clinical characterizations, management, and prognosis in immune checkpoint inhibitor-induced myelitis [0.03%]
免疫检查点抑制剂诱导性肌炎的临床特征、处理和预后
Yi-Xiao Li,Rui-Yun Wang,Zhi-Hang Lu et al.
Yi-Xiao Li et al.
The expanding clinical application of immune checkpoint inhibitors (ICIs) has led to increasing recognition of neurological immune-related adverse events, among which myelitis represents a rare but clinically significant complication. Curre...
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer [0.03%]
一种新型CDK4抑制剂可保护化疗治疗三阴性乳腺癌患者的髓样细胞
Ava Safaroghli-Azar,Laychiluh B Mekonnen,Ramin Hassankhani et al.
Ava Safaroghli-Azar et al.
Background: Despite advances in cancer treatment, chemotherapy remains a cornerstone of clinical practice. However, its efficacy is often compromised by dose-limiting haematologic toxicities. Recent strategies aim to enha...
Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis [0.03%]
抗PD-L1诱导的银屑病的临床特征、治疗及预后分析
Jian Xiao,Zhi Xia,Zhu Wu et al.
Jian Xiao et al.
Background: This study focuses on rare immune-mediated psoriasis induced by anti-PD-L1 drugs. Given that its clinical features have not been fully defined, the aim is to clarify the clinical manifestations, treatment, and...
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors [0.03%]
奥沙利铂白蛋白纳米粒联合TAS-102治疗复发难治性实体瘤的Ⅰ期临床研究
Nai-Jung Chiang,Li-Yuan Bai,I-Wei Ho et al.
Nai-Jung Chiang et al.
Onivyde, a liposome-encapsulated irinotecan, is used for advanced pancreatic, while TAS-102 (trifluridine/tipiracil) is indicated for metastatic colorectal and gastric cancers. This study aims to determine the maximum tolerated dose (MTD), ...
Approval of high-benefit oncology drugs in Japan: utilization of expedited regulatory pathways for the accelerated approved anticancer drugs [0.03%]
日本高效益肿瘤药物的审批：加速批准抗肿瘤药物的快捷监管通道的应用
Ayumi Taguchi,Naoki Matsumaru,Katsura Tsukamoto
Ayumi Taguchi
Early access to promising new drugs with superior efficacy compared to existing treatments is globally sought after. To facilitate such access, regulatory authorities in each country have implemented special regulatory measures that expedit...
Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis [0.03%]
奥瑞妥珠单抗联合利妥昔单抗和大剂量甲氨蝶呤治疗原发或继发中枢神经系统弥漫性大B细胞淋巴瘤的疗效及安全性：回顾性分析
Jiahao Zhou,Lingxiao Xing,Yi Miao et al.
Jiahao Zhou et al.
Central nervous system lymphoma (CNSL) are mainly diffuse large B-cell lymphomas (DLBCLs). Orelabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor and has shown single-agent activity in CNSL. This study aims to evaluat...